Alexander Karpeisky

Dr. Alexander Karpeisky

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Bone Reports
Verified
Journal Article
Open access
KFKristen B. Farrell
Kristen B. Farrell
AKAlexander Karpeisky
Alexander Karpeisky
DTDouglas H. Thamm
Douglas H. Thamm
SZShawn Zinnen
Shawn Zinnen
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone remains an important goal for achieving effective treatments. Drug targeting strategies have improved drug localization to bone by taking advantage of the high mineral concentration unique to the bone hydroxyapatite matrix, as well as tissue-specific cell types. The bisphosphonate molecule class binds specifically to hydroxyapatite and inhibits osteoclast resorption of bone, providing direct treatment for degenerative bone disorders, and as emerging evidence suggests, cancer. These bone-binding molecules also provide the opportunity to deliver other drugs specifically to bone by bisphosphonate conjugation. Bisphosphonate bone-targeted therapies have been successful in treatment of osteoporosis, primary and metastatic neoplasms of the bone, and other bone disorders, as well as refining bone imaging. In this review, we focus upon the use of bisphosphonate conjugates with antineoplastic agents, and overview bisphosphonate based imaging agents, nanoparticles, and other drugs. We also discuss linker design potential and the current state of bisphosphonate conjugate research progress. Ongoing investigations continue to expand the possibilities for bone-targeted therapeutics and for extending their reach into clinical practice.

9 November 2018 in The Oncologist
Verified
Journal Article
Open access
PDF file
SZShawn Patrick Zinnen
Shawn Patrick Zinnen
AKAlexander Karpeisky
Alexander Karpeisky
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
LPLarisa Plekhova
Larisa Plekhova
AAAlexander I. Alexandrov
Alexander I. Alexandrov
Lessons Learned: Results are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease. MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity. Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline. MBC-11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development. Background: MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). This first-in-human phase I dose escalation study assessed safety, tolerability, maximum tolerated dose (MTD), plasma pharmacokinetics, bone turnover, tumor biomarkers, and bone lesion activity by fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) imaging. Methods: Fifteen patients with advanced solid cancers and cancer-induced bone disease (CIBD) were treated with 0.5–10 mg/kg per day of MBC-11 administered daily for 5 days of every 4 weeks for up to four cycles. Results: Grade 1–2 myelosuppression, involving all lineages, was the principal toxicity. Two of three patients treated with 10 mg/kg experienced dose-limiting grade 4 neutropenia and thrombocytopenia (adverse event [AE] duration ≤5 days); the MTD was 5 mg/kg. Four of five patients with pretreatment elevations of the bone resorption marker TRAP5b (tartrate resistant acid phosphatase-5b) had persistent decrements. Six of 13 patients who reported baseline pain noted a reduction after MBC-11. 18F-FDG-PET/CT imaging demonstrated partial metabolic responses in three patients and stable metabolic responses in three other patients. SUVmax (standard unit of emission normalized to total uptake) was reduced by at least 25% in 110 (52%) of 211 bone lesions. Significant activity was noted across all doses, and myelosuppression increased with dose. Conclusion: At MBC-11 doses that were well tolerated, substantial reductions in metabolic activity of bone-associated cancer cells provide a foundation for further disease-directed efficacy studies.

1 May 1995 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
LBLeonid Beigelman
Leonid Beigelman
AKAlexander Karpeisky
Alexander Karpeisky
NUNassim Usman
Nassim Usman
The synthesis of phosphoramidites of 6-modified pyrimidine ribonucleosides and their incorporation into hammerhead ribozymes and influence on nuclease stability and catalytic activity is described.

1 May 2000 in Biochemistry
Verified
Journal Article
Closed access
DJDavid J.EArnshaw
David J.EArnshaw
MHMichelle L. Hamm
Michelle L. Hamm
JPJoseph A. Piccirilli
Joseph A. Piccirilli
AKAlexander Karpeisky
Alexander Karpeisky
LBLeo Beigelman
Leo Beigelman
MGMichael J. Gait
Michael J. Gait

15 November 2021 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
KFKristen B. Farrell
Kristen B. Farrell
SZShawn Zinnen
Shawn Zinnen
DTDouglas H. Thamm
Douglas H. Thamm
AKAlexander Karpeisky
Alexander Karpeisky

16 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
JKJost Klawitter
Jost Klawitter
MEMckay Easton
Mckay Easton
AKAlexander Karpeisky
Alexander Karpeisky
KFKristen Farrell
Kristen Farrell
DTDouglas H. Thamm
Douglas H. Thamm
SZShawn Patrick Zinnen
Shawn Patrick Zinnen
Background. The use of the bone-seeking properties of bisphosphonates (BPs) to target the delivery of therapeutic drugs is a promising approach for the treatment of bone metastases. Currently, the most advanced example of this approach is a gemcitabine-ibandronate conjugate (GEM-IB), where the bone-targeting BP ibandronate (IB) is covalently linked to the antineoplastic agent gemcitabine (GEM) via a spacer phosphate group. In the present study, we describe the development of a new analytical platform to evaluate the metabolism and pharmacokinetics of GEM-IB in mice and dogs and the results of proof-of-concept studies assessing the pharmacokinetics of GEM-IB in dogs and mice. Methods. We validated analytical platforms to analyze GEM-IB and five of its major metabolites IB, gemcitabine-5′-phosphate (GEMMP), gemcitabine (GEM), 2′,2′-difluoro-2′-deoxyuridine-5′-phosphate (dFdUMP), and 2′,2′-difluoro-2′-deoxyuridine (dFdU) and performed proof-of-concept pharmacokinetic studies in mice (5 mg/kg i.p.) and dogs (5 mg/kg i.v.). Results. Intra- and inter-run accuracy and imprecision (3 days) of the assays met the (FDA) acceptance criteria. The proof-of-concept plasma pharmacokinetic studies in mice showed AUCs of 1278, 10,652, 405, 38, 1063, 3389, and 38 h·ng/mL for GEM-IB, IB, GEMMP, dFdU-MP, GEM, and dFdU, respectively. In dog plasma, AUCs of 295, 5725, 83, 11, 1625, and 6569 h·ng/mL were observed for GEM-IB, IB, GEMMP, dFdUMP, GEM, and dFdU. Conclusions. Pharmacokinetic studies in dogs and mice showed that GEM-IB is rapidly converted to IB and GEM; dFdU is formed (from GEM) with a delay. The rapid disappearance of GEM-IB from circulation could be explained by a combination of metabolism and rapid distribution to tissue/bone.